Moreover, while many oncogenic events correlate with down-regulation of the UCEs in patients with HCC and mouse models, several conditions such as loss of tumor suppressors Trp53 and CDKN2A may lead to increased UCE expression (Fig. 1G) (16). The gene discussed is TP53; the disease is hepatocellular carcinoma.